2761 Phase II clinical trial of 6 mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours. (September 2015) - Nicum, S.; Boyle, L.; Strauss, V.; Gourley, C.; Hall, M.; Montes, A.; Abraham, J.; Clamp, A.; Kennedy, R.; Banerjee, S.; Roberts, C.